Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.68 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.68 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756592 | 0.87 | GRN (0.56) | GRNSORT1PSMB5CCR1SMN1; SMN2 | |
| SCHEMBL7468748 | 0.84 | ALDH1A1 (0.54) | GRNSORT1CCR1SMN1; SMN2NPC1 | |
| SCHEMBL30606650 | 0.81 | GRN (1.00) | GRNSORT1PSMB5CCR1SMN1; SMN2 | |
| SCHEMBL24283499 | 0.81 | GRN (1.00) | GRNSORT1PSMB5CCR1SMN1; SMN2 | |
| SCHEMBL24283500 | 0.81 | GRN (1.00) | GRNSORT1PSMB5CCR1SMN1; SMN2 | |
| SCHEMBL7463178 | 0.80 | GRN (0.68) | GRNSORT1PSMB5CCR1SMN1; SMN2 | |
| SCHEMBL12043743 | 0.80 | GRN (0.67) | GRNSORT1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7466235 | 0.79 | PSMB5 (0.51) | PSMB5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29093009 | 0.78 | GRN (0.64) | GRNSORT1PSMB5CCR1SMN1; SMN2 | |
| SCHEMBL29093013 | 0.78 | GRN (0.64) | GRNSORT1PSMB5CCR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | GRN 2719/4885SORT1 3907/4885PSMB5 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.